From Abbott halting sales of the Absorb to the recent FDA approval of the Biotronik Osirio, the last 18 months have seen major shifts in the market landscape for coronary revascularization devices. In this video Lumere cardiovascular expert Zach Eddy highlights:This Content is provided “AS IS”, with all faults and without any warranty of any kind; any and all warranties are expressly disclaimed. No information in this Content is, or should be construed as medical advice, a guarantee of any product safety or any endorsement of any product or service; use of this Content is at your own risk. Lumere shall not be liable, in any way, for any use of this Article or decisions made and/or actions taken based upon the contents herein. Discussion of experimental uses of drugs or medical product as described in this Content is for informational purposes only, and is not to be interpreted as an endorsement or encouragement of off-label use of any product.
- Whether the evidence demonstrates differences in outcomes between the major vendors’ drug-eluting stents (DES)
- How to gain significant leverage when negotiating with DES vendors
- The future landscape, including devices that have gained approval for European use